›› 2012, Vol. 24 ›› Issue (4): 256-260.doi: 10.3969/j.issn.1004-616x.2012.04.004

• 论著 • 上一篇    下一篇

食管癌组织中HER-2/neu蛋白表达和基因扩增的检测及其临床意义

汤永飞;詹 娜;黄亚冰;刘 琳   

  1. ( 武汉大学人民医院病理科,湖北 武汉 430060 )
  • 收稿日期:2011-07-06 修回日期:2011-10-29 出版日期:2012-07-30 发布日期:2012-07-30
  • 通讯作者: 詹 娜

Clinicopathological implication of HER-2/neu protein expression and gene amplication in esophageal carcinoma

TANG Yong-fei;ZHAN Na;HUANG Ya-bing;LIU Lin   

  1. (Department of Medical Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China)
  • Received:2011-07-06 Revised:2011-10-29 Online:2012-07-30 Published:2012-07-30
  • Contact: ZHAN Na

摘要: 目的: 检测食管癌组织中HER-2/neu蛋白表达及其基因扩增情况,并探讨其与食管癌患者临床病理指标的关系。方法:回顾性分析2000~2006年武汉大学人民医院收治的167例食管癌患者的临床资料。采用免疫组织化学和荧光原位杂交方法检测167例食管癌患者癌组织中 HER-2/neu蛋白表达及基因扩增情况。结果:食管癌组织中HER-2/neu蛋白表达水平与基因扩增存在一定相关性 (P<0.05), HER-2/neu蛋白的表达与食管癌分化程度和临床分期有关系 (P<0.05),而HER-2/neu基因扩增仅与食管癌临床分期有关系 (P<0.05)。HER-2/neu蛋白过表达和基因扩增阳性均可缩短食管癌患者的生存期 (P<0.05)。结论:HER-2/neu蛋白过表达及基因扩增可能是食管癌患者的一个预后指标,联合检测HER-2/neu蛋白表达水平及基因扩增程度对于食管癌的靶向治疗可能具有一定指导意义。

关键词: 食管癌, HER-2/neu, 免疫组织化学, 荧光原位杂交

Abstract: OBJECTIVE: To investigate HER-2/neu protein expression and gene amplication in esophageal carcinoma and to explore their clinicopathological correlations. METHODS:The clinical data of 167 patients admitted in Renmin Hospital of Wuhan University,from 2000 to 2006,were reviewed.The HER-2/neu protein expression and gene status in 167 esophageal carcinomas were evaluated using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).Categorical variables were compared by the Pearson chi-square test or Fisher's exact test and the survival rate was calculated by the Kaplan-Meier method and the log-rank test.RESULTS:HER-2 overexpression associated significantly with HER-2 gene amplification.There was a correlation between the overexpression of HER-2 and the differentiation of the carcinoma,the HER-2 gene amplification and the differentiation and stage of the carcinoma. According to univariate analysis,there was a significant difference in survival rates when cases with and without HER-2/neu overexpression or amplification were compared. CONCLUSION:HER-2/neu amplification may constitute an independent prognostic factor in esophageal squamous cancer patients,and patients exhibiting HER-2/neu amplification might constitute potential candidates for new adjuvant therapies which involve the use of humanized monoclonal antibodies.

Key words: esophageal carcinoma, HER-2/neu, immunohistochemistry, fluorescence in situ hybridization